Friday 6 November 2026 Export KYMR’s income statement to Excel — free account

Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $39.2 million, down 16.7% from fiscal 2024.

Revenue: +466.4%
EPS: −40.3%
Free cash flow: −186.6%
Total debt: −66.6%

Quarter to September 2026, against a year earlier

Insider buying

132.01 3.89 +3.04%

Follow KYMR

Alert me

Market cap: $10.9B
P/E: 0.0×
Fwd P/E: −31.6×
Dividend yield: —
F-score: 4/9
Altman Z: 23.22
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Valuation Filings

Kymera Therapeutics, Inc. 10-K filed Feb 26, 2026

Fiscal year 2025 · Period ended Dec 31, 2025 · Filed Feb 26, 2026 · accepted 7:15 AM ET · Document on sec.gov · Filing index

What changed

Item 1, Business Item 1A, Risk Factors Item 7, Management’s Discussion and Analysis

Item 7, Management’s Discussion and Analysis, against the 10-K filed Feb 27, 2025: 15 added · 4 removed · 26 modified; 7 with only figures updated; 6 moved without change

Kymera Therapeutics, Inc. 10-K filed Feb 26, 2026

What changed

Stockrow Weekly